EWTX · Edgewise Therapeutics, Inc.

The thesis

Edgewise Therapeutics' turn from muscular dystrophy to heart disease passed a regulatory checkpoint on 5 November 2026, and the case now rests on starting the STRATUS-HCM Phase 3 trial of EDG-7500 by 31 December 2026. The trial's placebo-controlled results settle whether the drug works and whether the shares earn a higher value. The company has published no readout date.

Edgewise reported favorable U.S. Food and Drug Administration (FDA) feedback from its End-of-Phase 2 meeting and has submitted the Phase 3 protocol, according to its 5 November 2026 release. The company also reported $1,743.9 million of cash and marketable securities at 30 September 2026. That is the first balance reported since the Servier sale closed on 10 July 2026.

The narrative is maturing: the Phase 3 plan has been public since 16 June 2026, and the shares opened at $43 on 5 November 2026 on the FDA news, according to market reports, but closed at $38.87 in adjusted daily closes. That close sits 19.6% below the 52-week high of $48.35.

Bullish and bearish views on Edgewise Therapeutics, Inc.

The bull case on Edgewise Therapeutics, Inc. (EWTX), in brief: FDA feedback clears the Phase 3 plan. The bear case: Efficacy against placebo remains unproven.

Bull case

• FDA feedback clears the Phase 3 plan. Edgewise said on 5 November 2026 that it submitted the STRATUS-HCM protocol after the meeting and receipt of the minutes, and that it remains on track to start this quarter. The release calls the feedback favorable and quotes no FDA wording. Company release
• Dosing would not depend on echocardiograms. Patients move from 50 mg to 100 mg to 150 mg daily at four-week intervals if the investigator judges the prior dose well tolerated, per the 5 November 2026 release. Edgewise says European and Japanese regulators gave generally consistent feedback on this plan. A simpler dosing routine would be a practical selling point if the drug reaches the market.
• The trial gives two independent chances. STRATUS-HCM enrolls about 600 adults, about 200 with obstructive and 400 with nonobstructive hypertrophic cardiomyopathy (HCM), and evaluates each group separately, per the 5 November 2026 release. The design also allows sample size expansion based on interim efficacy evidence.
• Reported cash is $1.74 billion. Edgewise held $68.7 million of cash and equivalents and $1,675.2 million of marketable securities at 30 September 2026, per its third-quarter 10-Q. Another $153.9 million of sale consideration sits in escrow. Q3 10-Q
• One broker raised sharply after the news. Raymond James raised its target to $85 from $66 on 6 November 2026. JPMorgan's target was $60 as of 20 August 2026, and HC Wainwright's was $57 as of 21 September 2026.

Bear case

• Efficacy against placebo remains unproven. The 16 June 2026 CIRRUS-HCM announcement covered 53 patients treated for 12 weeks without a placebo group, with a mean 24-point gain on the Kansas City Cardiomyopathy Questionnaire in obstructive disease. STRATUS-HCM runs 24 weeks with a different primary endpoint, change in peak oxygen consumption.
• The market faded the good news. Market reports dated 5 November 2026 put the prior close at $37.53 and the open at $43, and the adjusted close that day was $38.87. Adjusted daily closes show the shares down 12.8% over three months.
• Wedbush trimmed its target. Wedbush kept Outperform but cut its target to $51 from $53 on 5 November 2026, per MarketBeat, which put the average analyst target at $51.25. MarketBeat
• The third-quarter profit is one-time. Net income of $1,166.2 million, or $10.71 per basic share, reflects a $1,348.1 million gain on the sale, per the 4 November 2026 release. Edgewise has no revenue-stage product after the sale. Q3 results
• Taxes and trial costs draw on the cash. The 10-Q shows $155.3 million of third-quarter income tax expense and $108.9 million of accrued taxes at 30 September 2026. EDG-7500 research spending rose about $2.3 million from a year earlier on nonclinical and manufacturing costs, before any Phase 3 enrollment.

Price setup

The adjusted close on 5 November 2026 was $38.87, against a 52-week high of $48.35 and a 11 September 2026 close of $44.40. The reported $37.53 close before the FDA news sits below the 8 October 2026 close of $39.23, which had been the low of the prior slide.

The 14-day Relative Strength Index (RSI), a momentum gauge where readings under 30 are called oversold, was 58.9 on 5 November 2026, up from 46.4 on 21 October 2026 and 24.3 on 8 October 2026. The shares closed well under the $43 open on 5 November 2026, so that open marks the level where sellers met the FDA news.

Crowding evidence is thin. The third-quarter report has passed, and the 10-Q shows 109,482,763 shares outstanding at 31 October 2026 against 109,457,922 at 30 September 2026, so no large share issuance followed the sale. Edgewise reported inducement grants on 2 November 2026.

Catalysts, next 30 days

• No fixed date falls in the next 30 days. The first patient in STRATUS-HCM could be announced at any point inside the guided window.
• 31 December 2026: end of the guided window for the STRATUS-HCM start. Both the 4 November 2026 results and the 5 November 2026 release guide to a start by year-end. A start inside the window confirms execution. No announcement by that date would break this part of the case.

What would change the view

The case breaks if the STRATUS-HCM start moves into 2027, if a regulator places the trial on hold, or if the FDA objects to the echo-free dosing plan. Over the longer run, it breaks if EDG-7500 misses the peak oxygen consumption endpoint against placebo at Week 24 in both patient groups. A miss in nonobstructive disease alone would remove most of the planned enrollment from the case while leaving the obstructive study standing.

On price, a daily close below $36 would put the shares under the reported $37.53 close that preceded the FDA news. That would show the market has rejected both the FDA feedback and the reported cash balance as reasons to value the shares more highly.

What it trades with

The dated moves in this note follow company events: the 5 November 2026 jump at the open and fade by the close came on Edgewise's own FDA and earnings news. News from other developers of HCM drugs, such as Cytokinetics and Bristol Myers Squibb, bears on how the echo-free design is valued.

Two smaller links remain. Interest income was $16.5 million in the third quarter, so short-term rates affect results on a $1,675.2 million securities portfolio. Up to $1.1 billion of contingent Servier payments ties a part of Edgewise's value to the Becker and Duchenne muscular dystrophy programs it sold; this case gives those payments no value.